MedTrace Logo

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

NCT04540107 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-04-29

No results posted yet for this study

Summary

This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.

Conditions

  • Recurrent World Health Organization (WHO) Grade II Glioma
  • Recurrent WHO Grade III Glioma
  • WHO Grade II Glioma
  • WHO Grade III Glioma

Interventions

DRUG

Hyperpolarized Carbon C 13 Pyruvate

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Magnetic Resonance Spectroscopic Imaging

Undergo MRSI

Sponsors & Collaborators

  • GE Healthcare

    collaborator INDUSTRY

  • Sigma-Aldrich

    collaborator UNKNOWN

  • Phillips-Medisize

    collaborator UNKNOWN

  • National Cancer Institute (NCI)

    collaborator NIH

  • Susan Chang

    lead OTHER

Principal Investigators

  • Susan M Chang, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-11
Primary Completion
2027-01-31
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04540107 on ClinicalTrials.gov